TOP TEN perturbations for 39949_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39949_at
Selected probe(set): 213181_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39949_at (213181_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):2.6053524Number of Samples:3 / 6
| Experimental | stem cell differentiation study 47 (BMP-2; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (0d) |
| Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; IBMX; 1d)
Relative Expression (log2-ratio):2.345254Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; IBMX; 1d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 24 hours in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 1 day in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; TGFb; 7d)
Relative Expression (log2-ratio):2.2815828Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; TGFb; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)
Relative Expression (log2-ratio):-2.276247Number of Samples:3 / 2
| Experimental | prostate cancer study 8 (p. canc) |
| CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
| Control | prostate cancer study 8 (ptasc) |
| CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; IBMX; 7d)
Relative Expression (log2-ratio):-2.1662693Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; IBMX; 2d)
Relative Expression (log2-ratio):2.0443392Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; IBMX; 2d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
ulcerative colitis study 13 (inflamed) / normal colon epithelial cell sample
Relative Expression (log2-ratio):-2.0441437Number of Samples:3 / 3
| Experimental | ulcerative colitis study 13 (inflamed) |
| Colon epithelial cells from macroscopically inflamed gut areas derived from patients with established ulcerative colitis. Cells were obtained from microdissected epithelial fractions of surgically derived colon specimens. Histopathological examination of colon specimens displayed active lesions like erosions/ulcerations or crypt abscesses/cryptitis, and showed increased mononuclear infiltrates. | |
| Control | normal colon epithelial cell sample |
| Colon epithelial cells derived from microdissected epithelial fractions of normal colon tissue. Tissue was obtained during surgery from patients with tubulovillous adenoma of the colon or adenocarcinoma of the colon. |
oxyphilic adenoma study 1 / normal kidney tissue (fetal)
Relative Expression (log2-ratio):2.027585Number of Samples:4 / 2
| Experimental | oxyphilic adenoma study 1 |
| Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)
Relative Expression (log2-ratio):-1.9946413Number of Samples:3 / 11
| Experimental | HCC study 20 (CDX; Hep-G2; ectopic) |
| Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. | |
| Control | HCC study 20 (PDX; ectopic) |
| Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. |
breast cancer study 15 (inv. dc) / normal breast tissue
Relative Expression (log2-ratio):-1.9522247Number of Samples:5 / 5
| Experimental | breast cancer study 15 (inv. dc) |
| Primary invasive ductal carcinoma tissue sample derived from the breasts of female patients after surgery. | |
| Control | normal breast tissue |
| Tissue samples of the breast from healthy female individuals after breast reduction surgery. |